Urine drug testing of chronic pain patients. IV. Prevalence of gabapentin and pregabalin

Journal of Analytical Toxicology

Volumn 35, Issue 6, 2011, Pages 357-359

  Heltsley, Rebecca ^a   DePriest, Anne ^a   Black, David L ^a,b   Robert, Tim ^a   Caplan, Yale H ^c   Cone, Edward J ^d  

^a Aegis Sciences Corporation   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PREGABALIN;

ARTICLE; ASSAY; CHRONIC PAIN; CONCENTRATION (PARAMETERS); DRUG SCREENING; DRUG STRUCTURE; DRUG URINE LEVEL; HOSPITAL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PREVALENCE; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION STUDY;

EID: 79960329073     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/anatox/35.6.357     Document Type: Article

References (21)

1. R.H. Dworkin, M. Backonja, M.C. Rowbotham, R.R. Allen, C.R. Argoff, G.J. Bennett, M.C. Bushnell, J.T. Farrar, B.S. Galer, J.A. Haythornthwaite, D.J. Hewitt, J.D. Loeser, M.B. Max, M. Saltarelli, K.E. Schmader, C. Stein, D. Thompson, D.C. Turk, M.S.Wallace, L.R.Watkins, and S.M.Weinstein. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. 60: 1524-1534 (2003).
2. N.B. Finnerup, M. Otto, H.J. McQuay, T.S. Jensen, and S.H. Sindrup. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118: 89-305 (2005).
3. D.E. Moulin, A.J. Clark, I. Gilron, M.A. Ware, C.P. Watson, B.J. Sessle, T. Coderre, P.K. Morley-Forster, J. Stinson, A. Boulanger, P. Peng, G.A. Finley, P. Taenzer, P. Squire, D. Dion, A. Cholkan, A. Gilani, A. Gordon, J. Henry, R. Jovey, M. Lynch, A. Mailis-Gagnon, A. Panju, G.B. Rollman, and A. Velly. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res.Manag. 12: 3-21 (2007).
4. M. Gore, A. Sadosky, K.S. Tai, and B. Stacey. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin. Ther. 29: 1655-1670 (2007).
5. C. Pittenger and P.H. Desan. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. J. Clin. Psychiatry 68: 483-484 (2007).
6. M. Grosshans, J. Mutschler, D. Hermann, O. Klein, H. Dressing, F. Kiefer, and K. Mann. Pregabalin abuse, dependence, and withdrawal: a case report. m. J. Psychiatry 167: 869 (2010).
7. D.J. Cada, T. Levien, and D.E. Baker. Pregabalin. Hosp. Pharm. 41: 157-172 (2006).
8. G.L. Morris. Gabapentin. Epilepsia 40 Suppl 5: S63-S70 (1999).
9. B.L. Peterson. Prevalence of gabapentin in impaired driving cases inWashington State in 2003-2007. J. Anal. Toxicol. 33: 545-549 (2009).
10. D.R. Guay. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am. J. Geriatr. Pharmacother. 3: 274-287 (2005).
11. H.N. Bockbrader, L.L. Radulovic, E.L. Posvar, J.C. Strand, C.W. Alvey, J.A. Busch, E.J. Randinitis, B.W. Corrigan, G.M. Haig, R.A. Boyd, and D.L. Wesche. Clinical pharmacokinetics of pregabalin in healthy volunteers. J. Clin. Pharmacol. 50: 941-950 (2010).
12. F. Kolocouri, Y. Dotsikas, and Y.L. Loukas. Dried plasma spots as an alternative sample collection technique for the quantitative LC-MS/MS determination of gabapentin. Anal. Bioanal. Chem. 398: 1339-1347 (2010).
13. R. Oertel, N. Arenz, J. Pietsch, and W. Kirch. Simultaneous determination of three anticonvulsants using hydrophilic interaction LC-MS. J. Sep. Sci. 32: 38-243 (2009).
14. T. Wattananat and W. Akarawut. Validated LC-MS-MS method for the determination of gabapentin in human plasma: application to a bioequivalence tudy. J. Chromatogr. Sci. 47: 868-871 (2009).
15. M.M. Kushnir, J. Crossett, P.I. Brown, and F.M. Urry. Analysis of gabapentin in serum and plasma by solid-phase extraction and gas chromatography-mass spectrometry for therapeutic drug monitoring. J. Anal. Toxicol. 23: 1-6 (1999).
16. C.E.Wolf, J.J. Saady, and A. Poklis. Determination of gabapentin in serum using solid-phase extraction and gas-liquid chromatography. J. Anal. Toxicol. 20: 498-501 (1996).
17. T.A. Vermeij and P.M. Edelbroek. Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 810: 297-303 2004).
18. G.L. Lensmeyer, T. Kempf, B.E. Gidal, and D.A. Wiebe. Optimized method for determination of gabapentin in serum by highperformance liquid hromatography. Ther. Drug Monit. 17: 251-258 (1995).
19. S.Y. Chang and F.Y.Wang. Determination of gabapentin in human plasma by capillary electrophoresis with laser-induced fluorescence detection and acetonitrile stacking technique. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 799: 265-270 (2004).
20. A.B. O'Connor and R.H. Dworkin. Treatment of neuropathic pain: an overview of recent guidelines. Am. J.Med. 122: S22-S32 (2009).
21. R.A. Boyd, D. Turck, R.B. Abel, A.J. Sedman, and H.N. Bockbrader. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 40: 474-479 (1999).